NovaXS Biotech
NovaXS Biotech’s patent-pending technology, Telosis, is a needle-free drug delivery platform that allows patients to self-administer biologics subcutaneously or intramuscularly and track long-term treatment progress through IoT integration and a software app.
Headquarters
NovaXS Biotech
965 W Chicago Ave
Chicago
IL 60642
United States
NovaXS Biotech is a smart medical device start-up focused on advanced drug delivery and patients’ long-term health. Its patent-pending technology, Telosis, is a needle-free drug delivery platform that allows patients to self-administer biologics subcutaneously or intramuscularly and track long-term treatment progress through IoT integration and a software app.
NovaXS was founded in 2021. It is privately held, enrolled in the Berkeley SkyDeck, mHub MedTech Accelerator, USC Troylabs and Newchip Accelerator programmes and its investors include Baxter, Edward-Elmhurst Health, Courtyard Ventures, mHub Product Impact Hub, and Newgen Venture Partners.